Short answer
Cencora (COR) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Cencora updated fiscal year 2026 financial expectations on October 21, 2026.
Cencora 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Cencora updated fiscal year 2026 financial expectations on October 21, 2026
- Preliminary expectations remain subject to closing procedures, final adjustments and management review
- Fiscal 2027 outlook scheduled for discussion on November 4, 2026 earnings call
Item 7.01 · Regulation FD Disclosure
- Cencora agreed to acquire American Oncology Network through a merger, making AON a wholly owned subsidiary
- Transaction expands Cencora’s oncology platform and creates potential scale, integration, and synergy opportunities
- Closing depends on regulatory, stockholder, and other conditions, creating execution and timing risk
- Management flags leverage, investment-grade rating, integration, retention, and litigation risks for investors
- Exhibit 99.1 contains the accompanying transaction news release and additional deal terms
Item EX-99.1 · Exhibit EX-99.1
- Acquisition of AON, a 350-plus-provider oncology network across 21 states, expands Cencora’s community-oncology MSO platform
- $2.4B enterprise value, including $2.3B at closing and CVRs of up to $100M
- Approximately $1.7B expected closing cash outlay, assuming stockholders roll over 25% and Cencora owns 75%
- Cencora expects adjusted diluted EPS accretion in the second year post-closing, subject to regulatory and stockholder approvals
- Fiscal 2026 adjusted diluted EPS guidance raised to at least $17.90, versus previous $17.75 to $17.95 range
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cencora 8-K filings
Get the next COR 8-K as it lands
Follow COR for push alerts, or ask the research agent what this filing means.